419 related articles for article (PubMed ID: 33524139)
21. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.
Perez S; Kaspi A; Domovitz T; Davidovich A; Lavi-Itzkovitz A; Meirson T; Alison Holmes J; Dai CY; Huang CF; Chung RT; Nimer A; El-Osta A; Yaari G; Stemmer SM; Yu ML; Haviv I; Gal-Tanamy M
PLoS Genet; 2019 Jun; 15(6):e1008181. PubMed ID: 31216276
[TBL] [Abstract][Full Text] [Related]
22. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
Hamdane N; Jühling F; Crouchet E; El Saghire H; Thumann C; Oudot MA; Bandiera S; Saviano A; Ponsolles C; Roca Suarez AA; Li S; Fujiwara N; Ono A; Davidson I; Bardeesy N; Schmidl C; Bock C; Schuster C; Lupberger J; Habersetzer F; Doffoël M; Piardi T; Sommacale D; Imamura M; Uchida T; Ohdan H; Aikata H; Chayama K; Boldanova T; Pessaux P; Fuchs BC; Hoshida Y; Zeisel MB; Duong FHT; Baumert TF
Gastroenterology; 2019 Jun; 156(8):2313-2329.e7. PubMed ID: 30836093
[TBL] [Abstract][Full Text] [Related]
23. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
24. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
[TBL] [Abstract][Full Text] [Related]
25. Human genetics of HCV infection phenotypes in the era of direct-acting antivirals.
Nahon P; Cobat A
Hum Genet; 2020 Jun; 139(6-7):855-863. PubMed ID: 32100095
[TBL] [Abstract][Full Text] [Related]
26. Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful.
Abdelhamed W; El-Kassas M
J Viral Hepat; 2023 Feb; 30(2):148-159. PubMed ID: 36461645
[TBL] [Abstract][Full Text] [Related]
27. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
28. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
[TBL] [Abstract][Full Text] [Related]
29. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
[TBL] [Abstract][Full Text] [Related]
30. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
[TBL] [Abstract][Full Text] [Related]
31. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
[TBL] [Abstract][Full Text] [Related]
32. Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt.
Badawi R; Soliman S; Aboali L; Elkadeem M; Elfert A; Elguindy AMA; Ullah MS; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1300-1305. PubMed ID: 32940191
[TBL] [Abstract][Full Text] [Related]
33. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
Rinaldi L; Perrella A; Guarino M; De Luca M; Piai G; Coppola N; Pafundi PC; Ciardiello F; Fasano M; Martinelli E; Valente G; Nevola R; Monari C; Miglioresi L; Guerrera B; Berretta M; Sasso FC; Morisco F; Izzi A; Adinolfi LE
J Transl Med; 2019 Aug; 17(1):292. PubMed ID: 31462268
[TBL] [Abstract][Full Text] [Related]
34. Expression of pro- and anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCV-genotype-4.
Zekri AR; Bahnassy AA; Abdel-Wahab SA; Khafagy MM; Loutfy SA; Radwan H; Shaarawy SM
J Gastroenterol Hepatol; 2009 Mar; 24(3):416-28. PubMed ID: 19054267
[TBL] [Abstract][Full Text] [Related]
35. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
Celli R; Saffo S; Kamili S; Wiese N; Hayden T; Taddei T; Jain D
Arch Pathol Lab Med; 2021 Apr; 145(4):419-427. PubMed ID: 32810870
[TBL] [Abstract][Full Text] [Related]
36. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
[TBL] [Abstract][Full Text] [Related]
37. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M;
Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361
[TBL] [Abstract][Full Text] [Related]
38. Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
Tabu K; Mawatari S; Oda K; Kumagai K; Inada Y; Uto H; Saisyoji A; Hiramine Y; Hashiguchi M; Tamai T; Hori T; Fujisaki K; Imanaka D; Kure T; Taniyama O; Toyodome A; Ijuin S; Sakae H; Sakurai K; Moriuchi A; Kanmura S; Ido A
PLoS One; 2020; 15(8):e0237475. PubMed ID: 32790728
[TBL] [Abstract][Full Text] [Related]
39. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
